Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.

被引：0
|
作者：
Fong, Peter C. C.
Retz, Margitta
Drakaki, Alexandra
Massard, Christophe
Berry, William R.
Romano, Emanuela
De Bono, Johann S.
Feyerabend, Susan
Appleman, Leonard Joseph
Conter, Henry Jacob
Sridhar, Srikala S.
Shore, Neal D.
Linch, Mark David
Joshua, Anthony M.
Gurney, Howard
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
机构：
[1] Auckland City Hosp, Auckland, New Zealand
[2] Tech Univ Munich, Rechts Isar Univ Hosp, Munich, Germany
[3] Univ Calif Los Angeles, Los Angeles, CA USA
[4] Gustave Roussy Canc Campus, Villejuif, France
[5] Univ Paris Sud, Villejuif, France
[6] Duke Univ, Sch Med, Cary, NC USA
[7] Inst Curie, Paris, France
[8] Royal Marsden Hosp, London, England
[9] Studienpraxis Urol, Nurtingen, Germany
[10] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[11] Univ Western Ontario, Brampton, ON, Canada
[12] Princess Margaret Canc Ctr, Toronto, ON, Canada
[13] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[14] UCL, Inst Canc, London, England
[15] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia
[16] Macquarie Univ Hosp, Sydney, NSW, Australia
[17] Merck & Co Inc, Kenilworth, NJ USA
[18] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5010
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration -resistant prostate cancer (mCRPC).
    Parimi, Sunil
    Eigl, Bernhard J.
    Sunderland, Katherine
    Zulficiar, Muhammad
    Finch, Daygen L.
    Oja, Conrad D.
    Vergidis, Joanna
    Seto, Leanne Chung-Yon
    Azad, Arun
    Gleave, Martin
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] KEYNOTE-641: Phase III study of pembrolizumab (pembro) plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC)
    Graff, J. N.
    Burgents, J.
    Liang, L. W.
    Stenzl, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [43] Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
    Yu, Evan Y.
    Piulats, Josep M.
    Gravis, Gwenaelle
    Fong, Peter C. C.
    Todenhofer, Tilman
    Laguerre, Brigitte
    Arranz, Jose A.
    Oudard, Stephane
    Massard, Christophe
    Heinzelbecker, Julia
    Nordquist, Luke T.
    Carles, Joan
    Kolinsky, Michael P.
    Augustin, Marinela
    Gurney, Howard
    Tafreshi, Ali
    Li, Xin Tong
    Qiu, Ping
    Poehlein, Christian H.
    Schloss, Charles
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2023, 83 (01) : 15 - 26
  • [44] Pembrolizumab Combination Therapies in Patients With Metastatic Castration-Resistant Prostate Cancer: Cohorts A-C of the Phase 1b/2 KEYNOTE-365 Study
    Joshua, Anthony M.
    Gurney, Howard
    Retz, Margitta
    Tafreshi, Ali
    Fong, Peter
    Shore, Neal
    Romano, Emanuela
    Augustin, Marinela
    Piulats, Josep M.
    Berry, William R.
    Kolinsky, Michael Paul
    Sridhar, Srikala S.
    Conter, Henry Joacob
    Todenhofer, Tilman
    Appleman, Leonard J.
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    de Bono, Johann S.
    Yu, Evan Y.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 46 - 47
  • [45] PEMBROLIZUMAB plus LENVATINIB IN PATIENTS WITH ADENOCARCINOMA METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) OR TREATMENT-EMERGENT NEUROENDOCRINE MCRPC: PHASE 1B/2 KEYNOTE-365 COHORTS E/F
    Kramer, Gero
    Shore, Neal
    Joshua, Anthony
    Li, Xin Tong
    Poehlein, Christian
    Schloss, Charles
    De Bono, Johann
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A449 - A449
  • [46] PEMBROLIZUMAB plus VIBOSTOLIMAB IN PATIENTS WITH ADENOCARCINOMA METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) OR TREATMENT-EMERGENT NEUROENDOCRINE MCRPC: PHASE 1B/2 KEYNOTE-365 COHORTS G/H
    Shore, Neal
    De Bono, Johann
    Kramer, Gero
    Joshua, Anthony
    Li, Xin Tong
    Poehlein, Christian
    Schloss, Charles
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A455 - A455
  • [47] Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
    Yu, Evan Y.
    Kolinsky, Michael P.
    Berry, William R.
    Retz, Margitta
    Mourey, Loic
    Piulats, Josep M.
    Appleman, Leonard J.
    Romano, Emanuela
    Gravis, Gwenaelle
    Gurney, Howard
    Bogemann, Martin
    Emmenegger, Urban
    Joshua, Anthony M.
    Linch, Mark
    Sridhar, Srikala
    Conter, Henry J.
    Laguerre, Brigitte
    Massard, Christophe
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian H.
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2022, 82 (01) : 22 - 30
  • [48] Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients
    Yu, E.
    Piulats, J. M.
    Gravis, G.
    Fong, P. C. C.
    Todenhoefer, T.
    Laguerre, B.
    Arranz Arija, J. A.
    Oudard, S.
    Massard, C.
    Stoeckle, M.
    Nordquist, L. T.
    Carles, J.
    Kolinsky, M. P.
    Augustin, M.
    Gurney, H.
    Tafreshi, A.
    Li, X. T.
    Poehlein, C. H.
    Schloss, C.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S652 - S653
  • [49] KEYNOTE-365 Cohort B: Pembrolizumab Plus Docetaxel and Prednisone in Abiraterone or Enzalutamide-Pretreated Patients With Metastatic Castration-Resistant Prostate Cancer-New Data After an Additional 1 Year of Follow-Up
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 8 - 9
  • [50] Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): The phase III KEYNOTE-991 study.
    Gratzke, Christian
    Niu Cuizhen
    Poehlein, Christian Heinrich
    Burgents, Joseph E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345